301207.SZ
华兰疫苗
SZSE · Healthcare · C 制造业 · CN
CNY 17.08
−4.31%Year over year
Reported trailing growth
- Revenue
- +7.8%
- EBITDA
- —
- EBIT
- -6.7%
- EPS
- -5.5%
- Free cash flow
- +33.5%
- Operating cash flow
- +24.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -13.0%
- EBITDA
- -23.3%
- EBIT
- -31.6%
- Net income
- -29.4%
- EPS
- -29.6%
- Free cash flow
- +21.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026